keyword
MENU ▼
Read by QxMD icon Read
search

cetuximab AND radiotherapy

keyword
https://www.readbyqxmd.com/read/27895498/meta-analysis-of-outcomes-of-patients-with-stage-iv-colorectal-cancer-managed-with-chemotherapy-radiochemotherapy-with-and-without-primary-tumor-resection
#1
Ko-Chao Lee, Yu-Che Ou, Wan-Hsiang Hu, Chia-Cheng Liu, Hong-Hwa Chen
BACKGROUND: Colorectal cancer is the third leading cause of death worldwide. Currently, novel chemotherapeutic agents are first-line therapy for unresectable stage IV colorectal cancer, while benefits of noncurative primary tumor resection in advanced disease remain debatable. OBJECTIVE: This meta-analysis evaluated outcomes of patients with unresectable stage IV colorectal cancer receiving systemic chemotherapy with or without primary tumor resection. MATERIALS AND METHODS: A database search of PubMed and Cochrane Library databases identified 167 studies that were screened for relevance...
2016: OncoTargets and Therapy
https://www.readbyqxmd.com/read/27880014/inhibition-of-epithelial-mesenchymal-transition-by-cetuximab-via-the-egfr-gep100-arf6-amap1-pathway-in-head-and-neck-cancer
#2
Yoshifumi Matsumoto, Hiroyuki Sakurai, Yasunao Kogashiwa, Toru Kimura, Yuma Matsumoto, Takashi Shionome, Masatake Asano, Koichiro Saito, Naoyuki Kohno
BACKGROUND: Despite improved survival by the addition of a monoclonal antibody against epidermal growth factor receptor (EGFR), cetuximab, to chemotherapy or radiotherapy for squamous cell carcinoma of the head and neck (SCCHN), cetuximab by itself is not a potent antiproliferative agent against SCCHN. We aimed to elucidate working mechanism of cetuximab in SCCHN. METHODS: The effect of cetuximab on the proliferation, migration, invasion, epithelial-mesenchymal transition, and signaling events downstream of the EGFR were investigated in 4 SCCHN cell lines...
November 23, 2016: Head & Neck
https://www.readbyqxmd.com/read/27831000/targeted-therapies-for-the-treatment-of-non-small-cell-lung-cancer-monoclonal-antibodies-and-biological-inhibitors
#3
Ana P S Silva, Priscila V Coelho, Maristella Anazetti, Patricia U Simioni
The usual treatments for patients with non-small-cell lung cancer (NSCLC), such as advanced lung adenocarcinoma, are unspecific and aggressive, and include lung resection, radiotherapy and chemotherapy. Recently, treatment with monoclonal antibodies and biological inhibitors has emerged as an effective alternative, generating effective results with few side effects. In recent years, several clinical trials using monoclonal antibodies presented potential benefits to NSCLC, and four of them are already approved for the treatment of NSCLC, such as cetuximab, bevacizumab, nivolumab and pembrolizumab...
November 10, 2016: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/27825651/sequential-four-drug-chemotherapy-and-intensity-modulated-radiotherapy-for-larynx-preservation-in-resectable-advanced-larynx-and-hypopharynx-cancer-a-pilot-study
#4
Xuan Su, Caiyun He, Tao Tang, Weichao Chen, Zhaoqu Li, Yong Chen, Ankui Yang
OBJECTIVE: The value of additional use of cetuximab with the classical cisplatin, docetaxel and 5-fluorouracil regimen in larynx preservation remains unknown. This study was designed to resolve this issue and appraise its toxicity. MATERIALS AND METHODS: Thirteen untreated patients with stage III-IV larynx or hypopharynx squamous cell carcinoma were recruited and received two cycles of C+TPF regimen (cetuximab plus docetaxel, cisplatinand and 5-fluorouracil), followed by one more cycle of C+TPF and intensity-modulated radiotherapy (70Gy)...
January 2017: American Journal of Otolaryngology
https://www.readbyqxmd.com/read/27813277/comparison-between-weekly-cisplatin-enhanced-radiotherapy-and-cetuximab-enhanced-radiotherapy-in-locally-advanced-head-and-neck-cancer-first-retrospective-study-in-asian-population
#5
Sheh Rawat, Parveen Ahlawat, Anjali Kakria, Gaurav Kumar, Ranga Rao Rangaraju, Abhishek Puri, Manoj Pal, Deepika Chauhan, Bharti Devnani, Pranav Chadha
AIM: To present a direct comparison between chemotherapy-enhanced radiotherapy (CERT) and biotherapy-enhanced radiotherapy (BERT) in locally advanced head and neck cancer. METHODS: It is a retrospective analysis of 53 patients with locally advanced head and neck cancer treated from August 2006 to December 2008. For CERT, patients received weekly cisplatin (40 mg/m(2) ) and for BERT, a loading dose of 400 mg/m(2) of cetuximab given one week prior to radiotherapy followed by 250 mg/m(2) given weekly along with radiotherapy...
November 3, 2016: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27757500/-association-of-hpv-infection-p16%C3%A2-status-and-efficacy-of-radiotherapy-with-or-without-cetuximab-in-advanced-oropharyngeal-squamous-cell-carcinoma
#6
Carsten Nieder
No abstract text is available yet for this article.
October 18, 2016: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/27741378/assessing-feasibility-compliance-and-toxicity-of-concomitant-chemo-radiotherapy-in-head-and-neck-cancers-in-the-northern-territory-initial-experience-and-challenges
#7
Ajay Gupta, Siddhartha Baxi, Christopher Hoyne
INTRODUCTION: Comprehensive oncology services have recently been introduced in the Northern Territory (NT) enabling delivery of concurrent chemo-radiotherapy (CCRT) in locally advanced head and neck squamous cell carcinoma (LAHNSC). The purpose of this study is to assess feasibility, compliance and toxicity of CCRT in remote Australia. METHODS: Chart review was conducted for all patients >18 years, with biopsy-proven LAHNSC, receiving curative intent CCRT between January 2010 and September 2012...
July 1, 2016: Journal of Medical Radiation Sciences
https://www.readbyqxmd.com/read/27734748/cost-analysis-of-cetuximab-erbitux-plus-radiotherapy-ert-versus-concomitant-cisplatin-plus-radiotherapy-crt-within-an-nhs-oncology-unit-single-institution-a-pilot-study
#8
Brammer Caroline, Yahya Sundus, Dawson Dawn, Glaister Carol, Merrick Susan
OBJECTIVE: The aim of this feasibility study is to define the resource effectiveness of cetuximab vs cisplatin given concomitantly with radiotherapy for squamous cell carcinoma within a National Health Service clinical oncology unit. METHODS: 20 patients with Stage 3 or 4 head and neck squamous cell cancers were randomized to receive either cetuximab with radiotherapy (ERT) or cisplatin with radiotherapy concurrent with external beam radiotherapy 70 Gy in 35 fractions on a 1 : 1 basis over a 12-month duration...
December 2016: British Journal of Radiology
https://www.readbyqxmd.com/read/27730326/radiotherapy-for-elderly-patients-and-cetuximab-a-monocentric-study
#9
Alexander T Falk, Christophe Hébert, Antoine Tran, Marie-Eve Chand, Axel Leysalle, Juliette Thariat, Olivier Dassonville, Gilles Poissonnet, Alexandre Bozec, Esma Saada, Fréderic Peyrade, Karen Benezery
Concomitant radiotherapy and cetuximab association has shown superiority to exclusive radiotherapy for head and neck cancers. Data on this association are scarce for the elderly population despite its rising incidence. A retrospective monocentric data collection was performed in the Antoine Lacassagne Cancer Center in France. Inclusion criteria were: age >70 years at time of diagnosis, histologically proven head and neck epidermoid carcinoma, treated with radiotherapy combined with cetuximab. Thirty-five patients were included between 2008 and 2012...
October 11, 2016: European Archives of Oto-rhino-laryngology
https://www.readbyqxmd.com/read/27699537/optimizing-radiotherapy-in-hpv-associated-oropharyngeal-cancer-patients
#10
Johannes A Langendijk, Roel J H M Steenbakkers
Concurrent chemoradiation is considered the golden standard in the treatment of locally advanced OPC. However, given the very high survival rates in favorable HPV-positive OPC and the high rates of acute and late treatment-related side effects, de-escalation strategies have to be considered. In this chapter, the potential benefit of a number of de-escalation strategies is described, including of replacement of concurrent chemotherapy by cetuximab, radiation dose de-escalation based on response to induction chemotherapy, radiotherapy alone without systemic treatment, and limiting elective nodal target volumes for radiation...
2017: Recent Results in Cancer Research
https://www.readbyqxmd.com/read/27681990/extrapolation-of-survival-curves-from-cancer-trials-using-external-information
#11
Patricia Guyot, A E Ades, Matthew Beasley, Béranger Lueza, Jean-Pierre Pignon, Nicky J Welton
BACKGROUND: Estimates of life expectancy are a key input to cost-effectiveness analysis (CEA) models for cancer treatments. Due to the limited follow-up in Randomized Controlled Trials (RCTs), parametric models are frequently used to extrapolate survival outcomes beyond the RCT period. However, different parametric models that fit the RCT data equally well may generate highly divergent predictions of treatment-related gain in life expectancy. Here, we investigate the use of information external to the RCT data to inform model choice and estimation of life expectancy...
September 28, 2016: Medical Decision Making: An International Journal of the Society for Medical Decision Making
https://www.readbyqxmd.com/read/27644910/rectal-cancer-neoadjuvant-chemoradiotherapy
#12
REVIEW
Claus Rödel, Ralf Hofheinz, Emmanouil Fokas
The monolithic approach to apply the same schedule of preoperative 5-fluorouracil (5-FU)- or capecitabine-based chemoradiotherapy (CRT) to all patients with clinically staged TNM stage II/III rectal cancer need to be questioned. Five randomized trials have been completed to determine if the addition of oxaliplatin to preoperative 5-FU/capecitabine-based CRT offers an advantage compared with single-agent CRT. In contrast to the German CAO/ARO/AIO-04 trial, results from the ACCORD 12, STAR-01, PETACC-6 and NSAPB R-04 trials failed to demonstrate a significant improvement of early or late efficacy endpoints with the addition of oxaliplatin...
August 2016: Best Practice & Research. Clinical Gastroenterology
https://www.readbyqxmd.com/read/27635865/artificial-nutrition-dependence-after-cetuximab-versus-cisplatin-combined-with-radiotherapy-for-advanced-head-and-neck-cancer-a-propensity-score-matched-analysis
#13
Miho Ishimaru, Sachiko Ono, Sayaka Suzuki, Hiroki Matsui, Kiyohide Fushimi, Hideo Yasunaga
BACKGROUND: The purpose of this study was to compare the effect of cetuximab-based radiotherapy (RT) with cisplatin-based concomitant chemoradiotherapy (CCRT) on artificial nutrition dependence in locoregional advanced head and neck cancer. METHODS: We identified patients treated with cetuximab-based RT or CCRT between 2012 and 2014 in a Japanese national database, and used propensity score-matched analyses to evaluate artificial nutrition dependence for 30 days after starting chemotherapy and at hospital discharge...
September 16, 2016: Head & Neck
https://www.readbyqxmd.com/read/27623508/immunotherapy-in-head-and-neck-cancer-harnessing-profit-on-a-system-disruption
#14
REVIEW
Chloé Rancoule, Alexis Vallard, Sophie Espenel, Jean-Baptiste Guy, Yaoxiong Xia, Anis El Meddeb Hamrouni, Claire Rodriguez-Lafrasse, Cyrus Chargari, Eric Deutsch, Nicolas Magné
Immune system deregulation and evasion play a key role in cancers' evolution and progression, including squamous cell carcinoma of the head and neck (SCCHN). Development of basic research proposed a whole new vision of cancer treatment, based on a strong biological rational, and targeting intrinsic deregulations. Immunotherapies provide an encouraging strategy for patients' improved outcomes. Immune-based therapies could act on cancer growth and/or development throughout many pathways. If cetuximab is for now the only monoclonal antibody approved for SCCHN management, other strategies, e...
November 2016: Oral Oncology
https://www.readbyqxmd.com/read/27613373/pre-operative-chemoradiotherapy-using-capecitabine-and-cetuximab-followed-by-definitive-surgery-in-patients-with-operable-rectal-cancer
#15
Shouki Bazarbashi, Ayman Omar, Ali Aljubran, Ahmad Alzahrani, Nasser Alsanea, Alaa Abduljabbar, Samar Alhomoud, Luai Ashari, Khalid Balaraj, Hussein Soudy, Mohammad Neimatallah, Musa Fagih
BACKGROUND: Achieving a high rate of complete pathological response with pre-operative chemoradiotherapy in rectal cancer is an unmet need. We evaluated the efficacy and toxicity of the combination of cetuximab, capecitabine and radiation therapy in the pre-operative setting of localized rectal cancer. PATIENTS AND METHODS: Patients with clinically staged T3, T4 or nodepositive rectal cancer were treated with concurrent capecitabine and radiotherapy with weekly cetuximab starting one week before the start of radiation...
December 2016: Hematology/oncology and Stem Cell Therapy
https://www.readbyqxmd.com/read/27565887/survival-recurrence-and-toxicity-of-hnscc-in-comparison-of-a-radiotherapy-combination-with-cisplatin-versus-cetuximab-a-meta-analysis
#16
Jingwen Huang, Jing Zhang, Changle Shi, Lei Liu, Yuquan Wei
BACKGROUND: Cisplatin-based treatment has been considered the standard treatment regimen of HNSCC. Cetuximab is an emerging target therapy that has potential therapeutic benefits over cisplatin. Nevertheless, curative effects of cisplatin-based chemoradiotherapy (CRT) versus cetuximab-based bioradiotherapy (BRT) are still controversial. METHODS: Potentially eligible studies were retrieved using PubMed, Embase and Medline. Basic characteristics of patients and statistical data were collected...
August 26, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27561463/safety-of-drug-treatments-for-head-and-neck-cancer
#17
Rachel Galot, Jean-Pascal Machiels
INTRODUCTION: The treatment of squamous cell carcinoma of the head and the neck depends on the disease's stage. In locally-advanced stage disease, multimodal treatment strategies, including surgery, radiotherapy and chemotherapy, give the best outcome in terms of overall survival. Those treatments are not without negligeable adverse events, which can lead to late debilitating toxicities. In recurrent/metastatic disease, not amenable to surgery or radiation therapy, palliative chemotherapy is the most appropriate treatment...
September 9, 2016: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/27531866/neoadjuvant-radiotherapy-plus-radical-surgery-for-locally-advanced-stage-iii-iv-oral-cancer-analysis-of-prognostic-factors-affecting-overall-survival
#18
Eder-Czembirek Christina, Czembirek Cornelia, Selzer Edgar
OBJECTIVES: Preoperative radiotherapy followed by surgery is an effective treatment option for solid tumors including locally advanced squamous cell cancers of the head and neck region. Histopathologic response to radiation has been shown to be associated with survival. However, the relative prognostic importance of regression grade compared to other potential biomarkers has not been established yet. MATERIALS AND METHODS: One-hundred forty-four oral squamous cell carcinoma patients with stage III/IV disease were included in this analysis...
September 2016: Oral Oncology
https://www.readbyqxmd.com/read/27507562/combination-of-phosphotidylinositol-3-kinase-targeting-with-cetuximab-and-irradiation-a-preclinical-study-on-an-orthotopic-xenograft-model-of-head-and-neck-cancer
#19
Alexandre Bozec, Nathalie Ebran, Nina Radosevic-Robin, Emmanuel Chamorey, Hedi Ben Yahia, Serge Marcie, Mathieu Gautier, Frédérique Penault-Llorca, Gérard Milano
BACKGROUND: The purpose of this study was to investigate the effects of combining the phosphotidylinositol-3-kinase (PI3K) inhibitor buparlisib (BKM)120 with the anti-epidermal growth factor receptor (EGFR) agent cetuximab and radiotherapy (RT) on an orthotopic model of head and neck squamous cell carcinoma (HNSCC). METHODS: We evaluated the antitumor efficacy of BKM120, cetuximab, and RT, administered alone or in combination, using the human PIK3CA-mutated HNSCC cell line, CAL33, injected into the floor of the mouth of nude mice...
August 10, 2016: Head & Neck
https://www.readbyqxmd.com/read/27464948/induction-of-artificial-cancer-stem-cells-from-tongue-cancer-cells-by-defined-reprogramming-factors
#20
Koji Harada, Tarannum Ferdous, Dan Cui, Yasuhiro Kuramitsu, Takuya Matsumoto, Eiji Ikeda, Hideyuki Okano, Yoshiya Ueyama
BACKGROUND: The cancer stem cells (CSCs), a small subpopulation of cells in tumor are responsible for the tumor initiation, growth, recurrence and metastasis of cancer, as well as resistance of cancers to drugs or radiotherapy. CSCs are an important target for the development of novel strategies in cancer treatment. However, CSCs-targeted new anti-cancer drug discovery is currently hindered by the lack of easy and reliable methods for isolating, collecting and maintaining sufficient number of CSCs...
2016: BMC Cancer
keyword
keyword
104263
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"